Literature DB >> 22366234

Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study.

Sunil K Agarwal1, Gerardo Heiss, R Graham Barr, Patricia P Chang, Laura R Loehr, Lloyd E Chambless, Eyal Shahar, Dalane W Kitzman, Wayne D Rosamond.   

Abstract

AIMS: We examined the relationship between forced expiratory volume in 1 s (FEV(1)), airflow obstruction, and incident heart failure (HF) in black and white, middle-aged men and women in four US communities. METHODS AND
RESULTS: Lung volumes by standardized spirometry and information on covariates were collected on 15 792 Atherosclerosis Risk in Communities (ARIC) cohort participants in 1987-89. Incident HF was ascertained from hospital records and death certificates up to 2005 in 13 660 eligible participants. Over an average follow-up of 14.9 years, 1369 (10%) participants developed new-onset HF. The age- and height-adjusted hazard ratios (HRs) for HF increased monotonically over descending quartiles of FEV(1) for both genders, race groups, and smoking status. After multivariable adjustment for traditional cardiovascular risk factors and height, the HRs [95% confidence intervals (CIs)] of HF comparing the lowest with the highest quartile of FEV(1) were 3.91 (2.40-6.35) for white women, 3.03 (2.12-4.33) for white men, 2.11 (1.33-3.34) for black women, and 2.23 (1.37-3.59) for black men. The association weakened but remained statistically significant after additional adjustment for systemic markers of inflammation. The multivariable adjusted incidence of HF was higher in those with FEV(1)/forced vital capacity <70% vs. ≥70%: HR 1.44 (95% CI 1.20-1.74) among men and 1.40 (1.13-1.72) among women. A consistent and positive association with HF was seen for self-reported diagnosis of emphysema and chronic obstructive pulmonary disease, but not for asthma.
CONCLUSIONS: In this large population-based cohort with long-term follow-up, low FEV(1) and an obstructive respiratory disease were strongly and independently associated with the risk of incident HF.

Entities:  

Mesh:

Year:  2012        PMID: 22366234      PMCID: PMC3530346          DOI: 10.1093/eurjhf/hfs016

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  33 in total

1.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

Authors:  B R Celli; W MacNee
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

2.  Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project.

Authors:  D C Goff; D K Pandey; F A Chan; C Ortiz; M Z Nichaman
Journal:  Arch Intern Med       Date:  2000-01-24

3.  Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study.

Authors:  J S Gottdiener; A M Arnold; G P Aurigemma; J F Polak; R P Tracy; D W Kitzman; J M Gardin; J E Rutledge; R C Boineau
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

4.  Standardization of spirometry--1987 update. Statement of the American Thoracic Society.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1987-11

5.  Vital capacity and congestive heart failure. The Framingham study.

Authors:  W B Kannel; J M Seidman; W Fercho; W P Castelli
Journal:  Circulation       Date:  1974-06       Impact factor: 29.690

6.  Methodologic issues in the analysis of lung function data.

Authors:  W M Vollmer; L R Johnson; L E McCamant; A S Buist
Journal:  J Chronic Dis       Date:  1987

Review 7.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

8.  Vital capacity as a predictor of cardiovascular disease: the Framingham study.

Authors:  W B Kannel; H Hubert; E A Lew
Journal:  Am Heart J       Date:  1983-02       Impact factor: 4.749

9.  Epidemiology Standardization Project (American Thoracic Society).

Authors:  B G Ferris
Journal:  Am Rev Respir Dis       Date:  1978-12

10.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.

Authors:  P D Scanlon; J E Connett; L A Waller; M D Altose; W C Bailey; A S Buist; D P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

View more
  40 in total

1.  Changes in mid-life fitness predicts heart failure risk at a later age independent of interval development of cardiac and noncardiac risk factors: the Cooper Center Longitudinal Study.

Authors:  Ambarish Pandey; Minesh Patel; Ang Gao; Benjamin L Willis; Sandeep R Das; David Leonard; Mark H Drazner; James A de Lemos; Laura DeFina; Jarett D Berry
Journal:  Am Heart J       Date:  2014-11-12       Impact factor: 4.749

2.  Lung function decline over 25 years of follow-up among black and white adults in the ARIC study cohort.

Authors:  Maria C Mirabelli; John S Preisser; Laura R Loehr; Sunil K Agarwal; R Graham Barr; David J Couper; John L Hankinson; Noorie Hyun; Aaron R Folsom; Stephanie J London
Journal:  Respir Med       Date:  2016-02-11       Impact factor: 3.415

Review 3.  Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction: an epidemiologic perspective.

Authors:  Frank P Brouwers; Hans L Hillege; Wiek H van Gilst; Dirk J van Veldhuisen
Journal:  Curr Heart Fail Rep       Date:  2012-12

4.  Lung Function and Incident Kidney Disease: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Keiichi Sumida; Lucia Kwak; Morgan E Grams; Kunihiro Yamagata; Naresh M Punjabi; Csaba P Kovesdy; Josef Coresh; Kunihiro Matsushita
Journal:  Am J Kidney Dis       Date:  2017-07-26       Impact factor: 8.860

5.  Sleep Quality and Nocturnal Symptoms in a Community-Based COPD Cohort.

Authors:  Aditi Shah; Najib Ayas; Wan-Cheng Tan; Atul Malhotra; John Kimoff; Marta Kaminska; Shawn D Aaron; Rachel Jen
Journal:  COPD       Date:  2020-01-10       Impact factor: 2.409

6.  Rethinking Chronic Obstructive Pulmonary Disease. Chronic Pulmonary Insufficiency and Combined Cardiopulmonary Insufficiency.

Authors:  R Graham Barr
Journal:  Ann Am Thorac Soc       Date:  2018-02

Review 7.  Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction.

Authors:  Abhishek Jaiswal; Astha Chichra; Vinh Q Nguyen; Taraka V Gadiraju; Thierry H Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2016-02

8.  T1 measurements for detection of expansion of the myocardial extracellular volume in chronic obstructive pulmonary disease.

Authors:  Tomas G Neilan; Jessie P Bakker; Bhavneesh Sharma; Robert L Owens; Hoshang Farhad; Ravi V Shah; Siddique A Abbasi; Puja Kohli; Joel Wilson; Anthony DeMaria; Michael Jerosch-Herold; Raymond Y Kwong; Atul Malhotra
Journal:  Can J Cardiol       Date:  2014-08-19       Impact factor: 5.223

9.  Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling.

Authors:  Anna M Papinska; Maira Soto; Christopher J Meeks; Kathleen E Rodgers
Journal:  Pharmacol Res       Date:  2016-03-05       Impact factor: 7.658

10.  Lung function and heart disease in American Indian adults with high frequency of metabolic abnormalities (from the Strong Heart Study).

Authors:  Fawn Yeh; Anne E Dixon; Lyle G Best; Susan M Marion; Elisa T Lee; Tauqeer Ali; Jeunliang Yeh; Everett R Rhoades; Barbara V Howard; Richard B Devereux
Journal:  Am J Cardiol       Date:  2014-05-02       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.